Pharma Two B Ltd is a late clinical-stage pharmaceutical company focused on developing innovative, value-added combination products of previously approved oral drugs to enhance current treatment options for neurological disorders. Its lead (and sole) product candidate, P2B001, is a combined product designed to provide significant clinical benefits, improved tolerability through diminished side effects, and enhanced convenience and adherence for people with Parkinson’s disease.
Pharma Two B Ltd is a late clinical-stage pharmaceutical company focused on developing innovative, value-added combination products of previously approved oral drugs to enhance current treatment options for neurological disorders. Its lead (and sole) product candidate, P2B001, is a combined product designed to provide significant clinical benefits, improved tolerability through diminished side effects, and enhanced convenience and adherence for people with Parkinson’s disease.
2007
(19 years)
Founded
2050
IPO
NASDAQ
Listing Exchange
